En Carta Diagnostics
En Carta Diagnostics52About
What does En Carta Diagnostics do?
En Carta Diagnostics is a Paris-based DeepTech startup focused on revolutionizing molecular diagnostics by making them accessible for at-home use. Their proprietary platform aims to deliver the precision of laboratory PCR tests with the ease of use of rapid tests, providing results in approximately 30 minutes. The company is initially targeting early detection of Lyme disease and expanding into STI screening. Their technology utilizes aptamers for high-affinity and specific target binding, allow…
What is En Carta Diagnostics's revenue?
StartupHub estimates En Carta Diagnostics's annual revenue at $1.3M (range $774K to $4.1M, 69% confidence), based on comparable companies in the sector.
What is En Carta Diagnostics's valuation?
StartupHub estimates En Carta Diagnostics's effective valuation at $20.2M (range $12.5M to $30.0M, 24% confidence), based on comparable companies in the sector.
How much funding has En Carta Diagnostics raised?
En Carta Diagnostics has raised a total of $5M in funding. The most recent round on record is Seed.
Where is En Carta Diagnostics headquartered?
En Carta Diagnostics is headquartered in Paris, France.
When was En Carta Diagnostics founded?
En Carta Diagnostics was founded in 2022.
What industry does En Carta Diagnostics operate in?
En Carta Diagnostics operates in Biotechnology, HealthTech, Diagnostics, Medical Devices, MedTech, Biotech.
How many employees does En Carta Diagnostics have?
En Carta Diagnostics has approximately 12 people on record.
What is En Carta Diagnostics's current status?
En Carta Diagnostics's current operating status is: Inactive.
Galatek develops AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing, focusing on precision and reproducibility.
Digital batch record software for pharmaceutical and biotech manufacturing.
Develops and commercializes treatments for central nervous system disorders, including Rett syndrome.
A deep-tech company developing nanorobotic solutions for healthcare, initially targeting dental care applications.
MatrixCode is a research focus at the Freiburg Institute for Advanced Studies (FRIAS) investigating matrisome pathology.
An entrant is a company tagged Biotechnology whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.